论文部分内容阅读
目的 Amrubicin is allowed in relapsed small-cell lung carcinoma(SCLC)in Japan.The efficacy and safety of a combination ofamrubicin with carboplatin for SCLC as previously reported were various.This study aimed to summarize the currently availableevidence and evaluate the efficacy and safety of the combination for treating SCLC.